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Abstract
Background: As well as inducing direct oncolysis, reovirus treatment of melanoma is associated with activation of
innate and adaptive anti-tumour immune responses.
Results: Here we characterise the effects of conditioned media from reovirus-infected, dying human melanoma
cells (reoTCM), in the absence of live virus, to address the immune bystander potential of reovirus therapy. In
addition to RANTES, IL-8, MIP-1a and MIP-1b, reovirus-infected melanoma cells secreted eotaxin, IP-10 and the type
1 interferon IFN-b. To address the mechanisms responsible for the inflammatory composition of reoTCM, we show
that IL-8 and IFN-b secretion by reovirus-infected melanoma cells was associated with activation of NF-B and
decreased by pre-treatment with small molecule inhibitors of NF-B and PKR; specific siRNA-mediated knockdown
further confirmed a role for PKR. This pro-inflammatory milieu induced a chemotactic response in isolated natural
killer (NK) cells, dendritic cells (DC) and anti-melanoma cytotoxic T cells (CTL). Following culture in reoTCM, NK cells
upregulated CD69 expression and acquired greater lytic potential against tumour targets. Furthermore, melanoma
cell-loaded DC cultured in reoTCM were more effective at priming adaptive anti-tumour immunity.
Conclusions: These data demonstrate that the PKR- and NF-B-dependent induction of pro-inflammatory
molecules that accompanies reovirus-mediated killing can recruit and activate innate and adaptive effector cells,
thus potentially altering the tumour microenvironment to support bystander immune-mediated therapy as well as
direct viral oncolysis.
Background
Reovirus is a nonenveloped dsRNA virus which is highly
prevalent in the human population but produces few
clinical symptoms. Great interest has surrounded the
use of reovirus as an oncolytic agent due to its ability to
infect and induce death in a range of human malignan-
cies whilst sparing normal cells. Furthermore reovirus
has completed a number of early clinical trials and is
now being tested in the phase III setting [1-3]. Initial
studies indicated that the tumour specific oncolytic
activity was dependent upon the presence of an
activated Ras signalling pathway [4], although recent
data has indicated that susceptibility to reovirus infec-
tion may be influenced by additional complex mechan-
isms [5,6].
Previous work in our laboratory has indicated that
human melanoma cell lines, as well as freshly resected
tumour, undergo reovirus-induced apoptotic death in a
Ras/RalGEF/p38 dependent manner, and that this death
is accompanied by the release of inflammatory chemo-
kines and cytokines [7]. The release of pro-inflammatory
mediators following viral infection of tumour cells has
been observed with other oncolytic viruses such as
Herpes Simplex Virus (HSV) [8] and Newcastle disease
virus (NDV) [9].
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either naturally or via insertion of immune-activating
genes, have been shown to stimulate anti-tumour
immune responses, indicating their potential as immu-
notherapeutic as well as cytotoxic agents [10]. We have
previously shown that reovirus can exert immunogenic
effects against tumour cells by directly activating DC to
stimulate innate NK/T cell cytotoxicity [11], and by reo-
virus-induced tumour cell death facilitating the priming
of innate and adaptive anti-tumour responses in mouse
and human model systems [12-14]. However, the immu-
nogenicity of the pro-inflammatory milieu produced by
reovirus-infected melanoma cells (independent of the
effects of the virus itself which may be cleared rapidly in
vivo), and the signalling pathways involved in initiating
cytokine/chemokine production in tumour cells, have
not been addressed.
Chemokines can participate in the host response dur-
ing infection and inflammation by directing immune
effector cell migration. Four families of chemokines
have been described based on the position of conserved
cysteine residues [15]. Multiple chemokines can share
one common receptor, and each chemokine can poten-
tially bind to several different receptors, thereby allow-
ing multiple biological outcomes depending upon the
composition of the chemokine milieu and the cells
within the environment [16,17]. Furthermore, at sites of
inflammation, chemokines can form heteromers, poten-
tially inducing synergistic actions and enhancing leuko-
cyte migration and activation [18]. Hence, the induction
of multiple chemokines within an immunosuppressive
tumour microenvironment has the potential to induce
potent effects on immune effector cells to enhance ther-
apy. For example, in a murine B16 melanoma model,
ectopic expression and secretion of IP-10 by tumour
cells increased the number of NK cells at the tumour
site and prolonged NK cell dependent survival [19].
Data have also indicated a good correlation between
CXCR3 expression on T cells and an improved clinical
outcome in stage III melanoma patients [20].
The current study further investigates the chemokines
and cytokines (including type I IFNs) induced by reo-
viral oncolysis and the signaling pathways responsible
for the production of these pro-inflammatory mediators.
We also determine the effects of reoTCM, specifically in
the absence of active virus to exclude the direct conse-
quences of viral immune activation, on chemotaxis, acti-
vation and effector functions of NK cells, DC and CTL.
Materials and methods
Cell Culture and Reovirus
Skmel-28, Mel-624, Mel-888 and MeWo cells were
g r o w ni nD u l b e c c o ’s Modified Eagle Medium (DMEM)
(Invitrogen, Paisley, UK) supplemented with 10% (v/v)
foetal calf serum (FCS) (BioSera, Crawley Down, UK)
and 1% (v/v) L-glutamine (Sigma Aldrich). Peripheral
blood mononuclear cells (PBMC) were obtained, with
local ethics approval, from buffy coats of healthy blood
donors by Ficoll-Hypaque density centrifugation.
Human myeloid immature dendritic cells (DC) were
generated from human PBMC by MACS CD14+ selec-
tion (Miltenyi Biotech) or monocyte adherence as pre-
viously described [21]. Monocytes were cultured in
RPMI 1640 (Invitrogen Life Technologies) supplemented
with 10% FCS, 1% L-glutamine (complete media), 800
U/ml GM-CSF (Schering-Plough) and 500 U/ml IL-4
(R&D systems) for 5 days. NK cells were isolated from
human PBMC using MACS negative depletion kits fol-
lowing standard protocols as previously described (>
90% purity) [11]. NK cells were routinely cultured in
DMEM supplemented with 10% (v/v) human AB serum
(Sera Laboratories International Limited), 5% (v/v) foetal
calf serum and 1% (v/v) L-glutamine. Cytotoxic T lym-
phocytes (CTL) primed using reovirus infected mel-888
cells (moi 0.1) were generated in a 14 day priming assay
as detailed below. For chemotaxis assays, NK, DC and
CTL were resuspended in RPMI/0.5%Human AB/1%L-
Glutamine. All cell lines were grown at 37°C in an
atmosphere containing 5% CO2 and were routinely
tested for, and confirmed free of, Mycoplasma.W h e r e
indicated melanoma cells were treated with 2.5 mM
2-aminopurine (2-AP) (Sigma-Aldrich) or 50 μMc a f f e i c
acid phenethyl ester (CAPE) (Axxora, Nottingham, UK)
for 1 hour prior to, and during, treatment with reovirus.
Neither 2-AP nor CAPE at the doses used were directly
toxic to melanoma cells (data not shown). Reovirus type
3 Dearing strain was provided by Oncolytics Biotech
Inc. Virus titer was determined by a standard plaque
assay using L929 cells.
ELISA, Luminex and Flow Cytometry
IL-8 was detected using matched pair antibodies (BD
Pharmingen). IFN-b was detected using an IFN-b kit
(PBL Laboratories) as per the manufacturer’si n s t r u c -
tions. Eotaxin and IP-10 were detected using Luminex
technology (Biosource) according to the manufacturer’s
instructions. To assess NK cell phenotypic activation,
NK cells were labelled with CD69-APC/CD56-PE/
CD3PerCP antibodies (BD Pharmingen, R and D Sys-
tems). CD69 expression was determined on gated
CD56-PE
+ve/CD3-PerCP
-ve populations using a FACS-
Calibur instrument (BD Biosciences).
Western Blotting
Melanoma cell lines were seeded in 10 cm dishes and
left untreated or infected with 10pfu/cell reovirus for 4,
8, 12, 16, 20 and 24 hours prior to preparation of whole
cell lysates. Nuclear fractions were prepared using the
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ufacturers’ instructions. Whole cell lysates were pre-
pared using RIPA buffer supplemented with a protease
inhibitor cocktail (25 μl/ml, Sigma). 10 μg of total pro-
tein was loaded per lane for whole cell lysates. 20 μgo f
protein was loaded per lane for nuclear fractions. Pro-
teins were separated on a 10% SDS polyacrylamide gel
and transferred to a nitrocellulose membrane. Mem-
branes were probed with antibodies against total PKR
(BD Transduction Laboratories), I-B( S a n t aC r u z )a n d
p65 NF-B (Upstate). Antibody binding was detected
using the Odyssey system (LI-COR Biosciences UK,
Cambridge, UK). Equal lane loading was confirmed
using monoclonal antibody against b-actin (Sigma).
RNA Interference (RNAi) Studies
siRNAs were purchased from Ambion and reconstituted
to a concentration of 20 μM according to the manufac-
turers’ instructions. An siRNA oligonucleotide against
PKR (PKRV) and an irrelevant (green fluorescent pro-
tein-specific) control siRNA were used. The sequences
were, PKRV 5’ AAGGUGAAGGUAGAUCAAAGA-3’,
Control 5’ AAGGACGACGGAAACUACAAG-3’. Mela-
noma cells in 24 well plates and 10 cm dishes were
transfected with 100 nM (this concentration was opti-
mized by initial titration experiments) of siRNA. Control
siRNA transfections using equivalent concentrations
were included in each experiment. Transfections were
carried out in serum-free media using OligofectAMINE
(Invitrogen) for 6 hours. Media were replenished with
serum and supplements and cells were cultured in the
continued presence of siRNA overnight. After the over-
night incubation pre-existing media was removed from
the 24 well plates and replaced with 1 ml normal
growth media, and cells were left untreated or infected
with reovirus (0-10pfu/cell). Supernatants from these
cells were collected at 24 and 48 hours post reovirus
infection. For 10 cm dishes the pre-existing media was
removed and whole cell lysates were prepared and sepa-
rated by SDS-PAGE prior to probing with total PKR
antibody. Equal lane loading was confirmed using a
monoclonal antibody against b-actin.
Priming of Mel-888 Cytotoxic T Lymphocytes (CTL)
Mel-888 cells were seeded into tissue culture flasks and
allowed to adhere. DC, resuspended in a 50:50 mix of
DC media/reoTCM (from Mel-888), non-reoTCM, or
DC media/DMEM complete, were added to the Mel-888
cells at a 1:3 ratio (DC:tumour cell) overnight. Suspen-
sion cells were aspirated, leaving the tumour monolayer
intact, and cells were pelleted as previously described
[13]. Tumour loaded DC were then resuspended in CTL
media [RPMI supplemented with 7.5% (v/v) human AB
serum (Sigma), 1% (v/v) L-glutamine, 1% (v/v) sodium
pyruvate (Life Technologies), 1% (v/v) non-essential
amino acids (Life Technologies), 1% (v/v) HEPES (Life
Technologies), 20 μmol/L 2 -mercaptoethanol (Sigma),
and mixed with autologous PBMC at a ratio of 1:10 to
1:30. Cultures were supplemented with 5 ng/ml IL-7
(R&D systems) from day 1 and 30 U/ml IL-2 (R&D sys-
tems) on day 4 only. Cultures were re-stimulated using
the same protocol at day 7. Cells were harvested at day
14 and chromium release, CD107 degranulation and
intracellular IFN-g assessed as detailed below.
NK, DC and CTL chemotaxis
1.5 × 10
5 melanoma cells were plated in 6 well plates
and left overnight. Pre-existing media was removed and
replaced with DMEM/2%FCS/1% L-Glutamine and cells
were infected with 1 or 10pfu/cell reovirus for 48 hours.
Supernatants were collected and passed through a
0.2 μm Acrodisc syringe filter (Pall Life Sciences) and
then through a Viresolve
NFR filter (Millipore) to remove
virus. Chemotaxis was assessed using a transwell system.
650 μl filtered TCM from each of the four melanoma
cell lines was added to the lower chamber of triplicate
wells in a 24-well plate and a 5 μm( N Kc e l l sa n dC T L )
or 8 μm (DC) Thincert™ membrane (Greiner Bio-One)
placed in the well. 5 × 10
5 NK, DC or CTL (the anti-
Mel-888 CTL used in these chemotaxis experiments had
been previously primed using reovirus-infected Mel-
888-loaded DC as described [12]), resuspended in 100 μl
of low serum media were placed in the upper chamber
and plates were incubated at 37°C for 3 hours. Cells in
the lower wells were harvested, washed in FACS buffer
and labelled with 3 μl of CD56-PE (Serotec) and 3 μl
CD3-FITC (BD Biosciences) (NK cells), CD11c-PE (BD
Biosciences) (DC) or 3 μlC D 3 - F I T Ca n dC D 8 - P e r C P
(CTL) for 30 minutes at 4°C. Cells were washed, resus-
pended in 300 μl FACS buffer and transferred to a Tru-
Count™ tube (BD Biosciences) containing a known
number of fluorescent beads to provide the internal
counting control. A cell to bead ratio was determined
for each tube and a migration index was calculated by
normalising this ratio to those of controls in which
TCM harvested from uninfected tumour cells (‘non-
reoTCM’) was used.
CD107 degranulation and intracellular IFN-g staining
CD107 is a marker of lysosomal granule exocytosis and
was used as a marker of NK cell and CTL degranulation
as previously described [14]. NK cells and CTL were
incubated at a 1:1 ratio with tumour targets (K562, Mel-
888 or SKOV-3), in the presence of CD107a-FITC and
CD107b-FITC antibodies (BD Bioscience). Brefeldin A
(10 μg/ml) was added after 1 hour and cells were incu-
bated for a further 4 hours. Cells were then labelled
with CD8 PerCP (for CTL) or CD56-PE, CD3-PerCP
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cell cultures, and fixed in 1% PFA. Analysis was per-
formed by gating on CD8 populations (CTL) or on
CD56
+ve populations, and excluding cells labelled with
Dead Cell Discriminator and CD3 in the FL3 channel
(NK cells). For determination of intracellular IFN-g, cells
were treated as above, permeabilised with 0.3% saponin
and labelled with IFN-g-FITC (BD Pharmingen) prior to
flow cytometric analysis.
51Chromium cytotoxicity assay
Cytotoxicity of CTL was measured using a standard
4h o u r
51Cr assay [21] against Mel-888 or irrelevant
SKOV-3 targets. Percent lysis was calculated using the for-
mula: % lysis = 100 × (cpm experiment - cpm spontaneous
release)/cpm maximum release - cpm spontaneous release.
Results
Reovirus-infected melanoma cells secrete eotaxin, IP-10
and IFN-b
We have previously shown that reovirus infection of
human melanoma cell lines induces a potentially immu-
nogenic form of cell death with the release of RANTES
(CCL5), IL-8, MIP-1a (CCL3) and MIP-1b (CCL4) [7].
In addition, DC pulsed with reovirus-infected melanoma
cells secrete the chemokines CCL2, 3, 4, 5, 7, 8, 11
(eotaxin), and CXCL10 (IP-10), and these culture super-
natants induce NK cell chemotaxis [14]. We sought to
extend these studies by first testing for secretion of this
wider panel of chemokines from melanoma cell lines in
response to direct reovirus infection. Having previously
observed secretion of IFN-b (but not IFN-a)b yD C
pulsed with reovirus-infected Mel888 cells [14], we also
tested for type 1 IFN production by reovirus-infected
melanoma cells. Although the defective anti-viral IFN
response of tumour cells to oncolytic viruses can
account for tumour-specific oncolysis [22], this response
may not be completely abrogated. IFN-b in particular
m a yb ef u n c t i o n a l l ys i g n i f i c a n tw i t h i nt h et u m o u r
microenvironment, since its secretion by reovirus-
infected Mel888-loaded DC activates NK cells for
enhanced cytotoxicity [14].
In addition to RANTES, MIP-1a,M I P - 1 b and IL-8
[7], we detected eotaxin and IP-10 (but not CCL2, 7 and
8 - data not shown) in all four cell lines tested. Levels of
eotaxin were relatively low (Figure 1A), whilst IP-10 was
secreted at higher levels by all cell lines (Figure 1B).
Eotaxin is a member of the CC family of chemokines
and can selectively recruit eosinophils [23], which have
been associated with increased survival in a range of
cancers [24]. IP-10 is a CXC chemokine, and a chemoat-
tractant for monocytes, T lymphocytes and NK cells
which has been shown to elicit immune-mediated anti-
tumour effects in vivo [25].
Type 1 IFNs are secreted by normal cells to attenuate
viral infections, and mediate multiple immunoregulatory
functions that affect innate and adaptive responses [26],
including phenotypic and functional maturation of DC
[27] in the context of defence mechanisms against
tumours [28]. Dysfunctional IFN pathways in cancer cells
have been proposed as a mechanism by which replication
and cell lysis for viruses such as vesicular stomatitis virus
0
60
80
100
E
o
t
a
x
i
n
(
p
g
/
m
l
)
40
20
A
200
600
400
0
B
I
P
-
1
0
 
(
p
g
/
m
l
)
M
e
W
o
S
K
-
M
E
L
-
2
8
M
e
l
-
6
2
4
M
e
l
-
8
8
8
500
1500
1000
2000
2500
I
F
N
E
E
(
p
g
/
m
l
)
C
0
0 PFU
1 PFU
5 PFU
Figure 1 Melanoma cell lines produce eotaxin, IP-10 and IFN-b
in response to reovirus infection. Melanoma cell lines were
treated with 0 (open bars), 1 (pale grey bars) or 5 (dark bars) pfu/
cell reovirus and supernatants were collected after 48 hours and
assayed for eotaxin (A), IP-10 (B) and IFN-b (C). Results shown are
representative of 3 independent experiments.
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to tumour cells during oncolytic virotherapy [29]. More-
over, IFN-b has been genetically engineered into oncolytic
viruses to improve the therapeutic index between normal
and malignant cells [30], and to support priming of anti-
tumour immunity [31]. Therefore, we tested whether type
1 IFNs were secreted by reovirus-infected melanoma cells,
and found that IFN-b (Figure 1C), but not IFN-a (data
not shown), was produced by all 4 cell lines. These data
indicate that reovirus infection of melanoma cells induces
inflammatory chemokines capable of recruiting immune
effector cells, as well as IFN-b, which can support priming
of anti-tumour immunity in the context of oncolytic
virotherapy.
Reovirus infection activates NF-B in melanoma cells
leading to chemokine/cytokine secretion
Next, we investigated the signalling pathways involved in
chemokine/cytokine production following reovirus infec-
tion of melanoma cells. We focused on NF-B, as reo-
virus infection induces NF-B nuclear translocation to
activate pro-apoptotic gene expression in cultured HeLa
cells [32]. Furthermore, several of the chemokines/cyto-
kines produced in our system, such as IL-8, RANTES
and IFN-b, are known NF-B dependent genes [33].
NF-B resides in an inactive cytoplasmic form in con-
junction with I-B. Following I-B degradation, NF-B
translocates to the nucleus to initiate transcription.
Therefore, I-B degradation and increased expression of
the p65 NF-B subunit in nuclear fractions can be used
as indirect indicators of NF-B activation. In all 4 mela-
noma cell lines I-B degradation was observed within
16 hours of reovirus infection, which coincided with an
increase in nuclear p65 NF-B expression (Figure 2A,
B). To confirm a role for NF-B, we used IL-8 and
IFN-b as representative chemokines/cytokines, and pre-
treated the melanoma cell lines with the NF-Bs m a l l
molecule inhibitor CAPE [34] prior to infection with
reovirus. In all cell lines pre-incubation with 50 μM
CAPE led to significant decreases in IL-8 levels at all
doses of reovirus used (p < 0.05) (Figure 2C). Similar
inhibition of IFN-b secretion was observed following
CAPE pre-treatment (data not shown). Taken together
these data confirm that reovirus infection of melanoma
cells induces NF-B activation to initiate transcription
of chemokines and cytokines.
Chemokine and cytokine production by reovirus-infected
melanoma cells is mediated by a PKR dependent pathway
The double stranded RNA genome of reovirus is detect-
able by several cellular molecules which can activate
multiple signalling pathways. Having established that
reovirus infection induces NF-B activation, we next
sought to identify upstream mediators that might
provide a link between dsRNA detection and NF-B
activation. A major candidate was the serine/threonine
protein kinase PKR, which binds to, and is activated by,
dsRNA. PKR can inhibit viral translation via phosphory-
lation of the translation initiation factor eIF-2a and ras-
related defective PKR signaling has been implicated in
the tumour specificity of reovirus replication and onco-
lysis [35]. PKR is also involved in the anti-viral type 1
IFN response, which is at least partially functional in
our system, as demonstrated by secretion of IFN-b fol-
lowing reovirus infection (Figure 1C). Significantly, PKR
is involved in the canonical NF-B signalling transduc-
tion pathway [36], and can induce NF-B activation via
phosphorylation of I-B [37]. We investigated the role
of PKR in inflammatory chemokine/cytokine secretion
by reovirus-infected melanoma cells, again using IL-8/
IFN-b as representative readouts. Initial western blot
analysis confirmed that all cell lines expressed baseline
levels of total and phosphorylated PKR, which did not
change on reovirus infection (data not shown). Cells
were then pre-treated with the PKR inhibitor 2-AP prior
to reovirus infection and significant reductions in IL-8
(p < 0.05) (Figure 3A) and IFN-b (data not shown) were
observed in 3 out of 4 cell lines. To further confirm
these findings we used siRNA to specifically knockdown
PKR expression [38]. Mel-624 cells were used, following
initial optimization studies, as these were found to have
the highest transfection efficiency of the 4 cell lines
(data not shown). PKR siRNA decreased total PKR
expression by approximately 50% compared with control
siRNA treated cells (Figure 3B). This knockdown was
found to correlate to an approximate 40% reduction in
IL-8 secretion 24 hours post reovirus infection (p <
0.05) (Figure 3C). These data confirm a role for PKR, in
addition to NF-B, in induction of inflammatory chemo-
kines/cytokines upon reovirus infection and oncolysis.
Virus-filtered tumour conditioned media from reovirus-
treated melanoma cells (reoTCM) induces a chemotactic
response in NK cells, DC and CTL
Previously identified components of reoTCM, such as
MIP-1a, MIP-1b, RANTES, [7], Figure 1B) are chemoat-
tractants to a variety of immune cell types. We tested
whether reoTCM could induce a chemotactic response
in relevant immune effector cells (NK, DC, CTL). To
address the potential immunogenic bystander effects of
the chemokines and cytokines independent of direct
consequences of the virus itself [11], reoTCM was
passed through a Viresolve
NFR filter, and successful
removal of reovirus was confirmed by a negative plaque
assay on L929 cells (data not shown).
Isolated NK cells actively migrated toward reoTCM
(Figure 4A), with an approximate 2-3 fold increase in
migration in 3 out of 4 cell lines (p < 0.05). Similar
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Figure 2 Reovirus infection activates NF-B in melanoma cells to induce cytokine secretion. (A) Melanoma cell lines were seeded in
100 mm dishes and treated with 10pfu/cell reovirus. At 4, 8, 12, 16, 20 and 24 hours post-infection whole cell lysates were prepared and I-B
assessed by western blot. (B) Melanoma cell lines were seeded as in (A), and nuclear fractions were prepared and western blotted for NF-B p65.
Densitometry data is shown underneath each blot. (C) Melanoma lines were seeded in 24 well plates and pre-treated with 50 μM CAPE, or
equivalent DMSO solvent concentrations, for 2 hours prior to addition of reovirus at the indicated doses. Supernatants were collected after 48
hours and IL-8 levels determined using ELISA. Data are representative of at least 3 independent experiments. * indicates P < 0.05, by Student’s
t-test.
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Page 6 of 13Figure 3 PKR mediates cytokine production by reovirus treated melanoma cells. (A) Melanoma cell lines were seeded in 24 well plates
and pre-treated with 2.5 mM 2-AP or equivalent PBS controls, for 2 hours prior to addition of reovirus at the indicated doses. Supernatants were
collected after 48 hours and IL-8 levels determined. Data are representative of at least 3 independent experiments. * indicates P < 0.05, by
Student’s t-test. (B) Mel-624 tumour cells were seeded in 100 mm dishes and transfected with 100 nM PKRV or irrelevant control siRNA. Cell
lysates were prepared and western blotted for total PKR, with b-actin used to confirm equal track loading. (C) Mel-624 cells were seeded in 24
well plates and transfected with 100 nM PKRV or irrelevant control siRNA; reovirus was then added at the indicated doses. Supernatants were
collected 24 and 48 hours later and IL-8 levels determined. Data are representative of two independent experiments. * indicates P < 0.05 by
Student’s t-test.
Steele et al. Molecular Cancer 2011, 10:20
http://www.molecular-cancer.com/content/10/1/20
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reoTCM derived from the same three cell lines (p <
0.05) (Figure 4B). Anti-tumour effector CTL generated
by priming in the presence of reo-infected mel-888 [12]
gave comparable results (Figure 4C); increases in cell
migration were observed for MeWo, SKMEL-28 (p <
0.05) and Mel-888 (although this did not reach statisti-
cal significance). Mel-624 reoTCM failed to induce a
significant chemotactic response in any cell type. Inter-
estingly, this cell line exhibited lower levels of MIP-1a,
MIP-1b and IP-10 secretion following reovirus infection
([7], Figure 1B). Although these data do not precisely
define the single/multiple chemokines responsible for
chemotaxis, they show that NK cells, DC and CTL are
capable of actively migrating toward melanoma cells
undergoing reoviral induced cell death.
ReoTCM from reovirus-treated melanoma cells induces
phenotypic and functional activation of NK cells
Previous work in our laboratory has demonstrated that
secretion of IFN-b by DC loaded with reovirus infected
Mel-888 cells stimulated NK cell cytotoxicity toward
melanoma targets [14]. Having demonstrated that
reoTCM contains IFN-b and that virus-free reoTCM
can be chemoattractant to immune effector cells (Figure
1C, 4A), we investigated the immunogenic potential of
reoTCM with regard to NK cell activation and innate
anti-tumour immune priming. Culture of isolated NK
cells in Mel-888 reoTCM upregulated the expression of
the NK activation marker CD69 (Figure 5A) and
increased levels of NK degranulation and intracellular
IFN-g (Figure 5B) following co-culture with Mel-888
targets. ReoTCM-treated NK cell degranulation was also
demonstrated against K562 targets (although not in the
absence of targets - data not shown) demonstrating the
non-specific nature of this innate response. Hence, the
pro-inflammatory environment induced by reovirus
infection of melanoma cells is capable, even in the
absence of replicating virus, of inducing lytic activity
and intracellular IFN-g in activated NK cells, thereby
potentially supporting innate anti-tumour effects within
a treated tumour.
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Figure 4 Isolated NK cells, DC and CTL migrate toward virus filtered reoTCM.5×1 0
5 NK cells (A), DC (B) or CTL (C) were resuspended in
RPMI + 0.5% human AB serum + 1% L-Glutamine and placed in a 5 μm (NK + CTL) or 8 μm (DC) Thincerts™ to separate cells from virus
filtered reoTCM/non-reoTCM. Migration was assessed after 3 hours by labelling cells with CD11c-PE (DC), CD56-PE/CD3-FITC (NK cells) or CD3-
FITC/CD8-PerCP (CTL) and then using Trucount™ tubes to provide an internal counting control. A cell:bead ratio was determined for each tube
and a migration index calculated by normalising this ratio to those of non-reoTCM controls. Data represents means of triplicate wells +/- SEM
and is representative of 4 independent donors. * indicates P < 0.05 by Student’s t-test.
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prime human naïve anti-melanoma CTL
We have previously shown that reoTCM can induce
phenotypic maturation of DC [11], and that DC loaded
with infected Mel-888 cells can prime tumour specific
CTL in the continued presence of reovirus [12]. To
address the adaptive immunogenic potential of virus-
free reoTCM, DC were cultured in reoTCM (or medium
from uninfected non-reoTCM controls), loaded with
Mel-888 cells and added to PBMC. The generation of
anti-tumour CTL over 14 days was then assessed as pre-
viously described [13]. PBMC proliferation was mea-
sured using trypan blue exclusion to determine viable
cell number and was greater in reoTCM priming cul-
tures than non-reoTCM controls (Figure 6A). Moreover,
this proliferation was associated with increased levels of
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Figure 5 NK cells cultured in reoTCM are activated against melanoma cell targets. (A) NK cells were cultured in the presence of virus-
filtered reoTCM/non-reoTCM overnight and CD69 expression determined. (B) NK cells were cultured in the presence of filtered reoTCM or non-
reoTCM for 48 hours and then co-cultured with Mel-888 tumour targets prior to CD107 and intracellular IFNg assessment. Results shown are
gated on CD56
+ve/CD3
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with an evolving Th1 adaptive T cell response (Figure
6B). A chromium cytotoxicity assay was used to deter-
mine the lytic ability of CTL generated by reoTCM and
non-reoTCM-treated tumour-loaded DC. Whilst some
specific anti-Mel888 CTL activity was seen under non-
reoTCM DC conditions, levels of killing were signifi-
cantly higher when reoTCM-conditioned DC were used
for CTL priming (approximately 70% lysis compared
with 30%) (p < 0.05) (Figure 6C). No killing of irrelevant
SKOV-3 tumour targets was observed. In addition, CTL
CD107 degranulation and intracellular IFN-g, in the pre-
sence of Mel888 targets (but not SKOV-3, data not
shown), was also higher after reoTCM priming com-
pared with their non-reoTCM counterparts (Figure 6D).
Although these cytotoxicity assays do not address the
MHC class I restriction or antigen specificity of killing
(which are potential confounding factors when using an
allogeneic tumour cell line as an antigen source for
human CTL priming), we have previously shown in this
system that specific anti-Mel888 CTL include T cells
which recognize the tumour-associated antigen MART-
1 [12,13], demonstrating that these responses include
targeting of antigens relevant to anti-tumour therapy.
Hence, in addition to activation of innate NK cell anti-
melanoma activity, virus-free reoTCM is able to support
effective priming of a specific adaptive CTL response.
Discussion
Reovirus is a tumour-specific oncolytic virus currently
under clinical investigation [39,40]. We, and others,
have shown that reovirus is one of several therapeutic
viruses whose activity can be mediated via activation of
an anti-tumour immune response, as well as the direct
oncolytic effect of viral replication in tumour cells [10].
Whether the immune response to viral therapy is pro-
blematic, due to rapid systemic inactivation of the agent,
or actively therapeutic, via provision of a ‘danger’ signal
within an otherwise immunosuppressive tumour micro-
environment, likely depends on multiple factors. These
include route of virus delivery (intratumoural versus
intravenous), the pre-existing immune status of the
patient and the mechanisms by which the virus natu-
rally, or via genetic modification, targets tumour cells.
Consequently, various immunomodulatory strategies
have been employed to improve oncolytic viral therapy,
ranging from immunosuppression to improve viral per-
sistence in the circulation [41], through to enhancement
of immune activation via insertion of transgenes, such
as GMCSF, into the viral genome [42].
We have previously shown that i) reovirus induces
apoptotic death in human melanoma cells and that this
death is associated with secretion of inflammatory che-
mokines/cytokines [7], ii) reovirus directly activates DC
in the absence of tumour cells [11], and iii) reovirus-
infected melanoma cells can activate innate and adaptive
arms of the anti-tumour immune response [12-14].
H o w e v e r ,t h e s ed a t aw e r eg e n e r a t e di nt h ec o n t i n u e d
presence of active virus. Since reovirus itself is directly
immunostimulatory [11], removal of the virus from
reoTCM via filtration allowed us to specifically investi-
gate the additional, bystander immunogenic effects of
the inflammatory environment potentially generated in
treated tumours. The immunogenic component of
human reoviral therapy may have particular clinical rele-
vance, since levels of reovirus replication in freshly
resected melanoma cells may be low [7]. Furthermore,
the switch from a suppressive to an inflammatory
tumour milieu may persist even after the virus has been
cleared [43].
We extended our previous analysis of the chemokines
and cytokines produced by reovirus-infected human
melanoma lines, and showed that eotaxin and IP-10
were also secreted (Figure 1). Interestingly, we also
detected IFN-b (but not IFN-a) under these conditions,
illustrating that an anti-viral type 1 IFN response is par-
tially functional in these tumour cells. This is particu-
larly important as IFN-b is involved in innate immune
activation by DC loaded with reovirus-infected cells
[14]. Moreover, IFN-b has been engineered into other
oncolytic viruses to increase the therapeutic index
between malignant and normal cells, and to enhance
anti-tumour immune activation [30].
Although the mechanisms responsible for the inflam-
matory response of tumour cells to reovirus infection
have not been addressed to date, previous studies have
implicated a role for NF-B since i) reovirus infection
initiates translocation of the p50/p65 NF-Bs u b u n i t st o
the nucleus and activates pro-apoptotic gene expression
[32,44], ii) reovirus induces apoptosis in melanoma cells
[7], and iii) NF-B is involved in the production of che-
mokines and cytokines such as IL-8 and IFN-b [33].
This study confirms that reovirus infection of melanoma
cells activates NF-B, as assessed by I-B degradation
and accumulation of nuclear p65, and that blocking NF-
B with the small molecule inhibitor CAPE significantly
decreases production of IL-8 and IFN-b (Figure 2).
Importantly, this effect was seen across all 4 cell lines,
suggesting that common signalling pathways are acti-
vated following reovirus infection of melanoma. To
address viral sensing and signaling molecules that may
lie upstream of NF-B, we investigated the dependence
of IL-8 and IFN-b production on PKR, as one of a num-
ber of candidate dsRNA sensors. PKR is involved in the
tumour specificity of reoviral oncolysis (although the
precise mechanism remains to be fully elucidated), and
t h ea n t i - v i r a lt y p e1I F Nr e s p o n s e[ 3 5 ] .W ef o u n d ,v i a
small molecule blockade and siRNA knockdown, that
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noma cells following reovirus infection (Figure 3).
Although we have been unable to detect any significant
change in total or phosphorylated PKR following reo-
virus infection of melanoma cell lines (data not shown),
these data suggest that dsRNA detection by PKR initi-
ates activation of NF-B-dependent chemokines and
cytokines in tumour cells. These findings are in agree-
ment with previous observations following direct infec-
tion of DC [11]. However, further work is required to
fully characterize the signaling pathways responsible for
the immunogenic nature of reovirus-induced tumour
cell oncolysis.
Filtered reoTCM induced a chemotactic response in
NK cells, DC and anti-tumour CTL (previously primed
using reovirus-infected tumour cells) (Figure 4), suggest-
ing that the immunogenic milieu in treated tumours has
the potential to recruit a range of immune cells capable
of viral detection and innate/adaptive effector functions.
With regard to improving access of primed CTL to
tumours, this finding is consistent with previous murine
data showing greater persistence of adoptively transferred
antigen specific T cells within tumours undergoing VSV-
mediated oncolysis [45]. To date we have not specifically
identified which of the secreted chemokine(s) are respon-
sible for NK cell, DC and CTL migration. It is possible
that multiple chemokines may act in combination to
engage a variety of receptors to induce a particular phy-
siological response [16]. The ability of reoTCM to sup-
port activation of innate (Figure 5) and adaptive (Figure
6) immune responses against human melanoma cells
shows that the immunogenic effects of reovirus induced
cell death are not dependent on the continued presence
of virus once an initiating danger signal has been deliv-
ered. Therefore, even if viral replication in patients is lim-
ited by neutralization, for example following repeated
administration [46], the immunogenic response of
tumour cells to reovirus infection may be sufficient to
induce continuing anti-tumour effects.
Overall, the present study shows that reovirus infection
of human melanoma cells induces a range of chemokines
and cytokines capable of inducing a chemotactic response
in NK cells, DC and primed CTL. This inflammatory
response is dependent upon NF-B and PKR and is suffi-
cient, in the absence of live virus, to support priming of
innate and adaptive anti-tumour immunity. This data sup-
ports the potential of bystander activation of human anti-
tumour immunity by reovirus killing of tumour cells, even
if persistent viral replication is limited by the anti-viral
immune response.
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